NIOX vs. MXCT, EKF, CREO, IUG, NCYT, BELL, POLX, IHC, AVO, and MHC
Should you be buying NIOX Group stock or one of its competitors? The main competitors of NIOX Group include MaxCyte (MXCT), EKF Diagnostics (EKF), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), Belluscura (BELL), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), and MyHealthChecked (MHC). These companies are all part of the "medical devices" industry.
NIOX Group vs.
NIOX Group (LON:NIOX) and MaxCyte (LON:MXCT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation.
MaxCyte received 152 more outperform votes than NIOX Group when rated by MarketBeat users. However, 100.00% of users gave NIOX Group an outperform vote while only 68.92% of users gave MaxCyte an outperform vote.
NIOX Group has a net margin of 30.00% compared to MaxCyte's net margin of -77.97%. NIOX Group's return on equity of 13.52% beat MaxCyte's return on equity.
35.2% of NIOX Group shares are owned by institutional investors. Comparatively, 70.5% of MaxCyte shares are owned by institutional investors. 46.7% of NIOX Group shares are owned by insiders. Comparatively, 1.5% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, NIOX Group had 1 more articles in the media than MaxCyte. MarketBeat recorded 1 mentions for NIOX Group and 0 mentions for MaxCyte. NIOX Group's average media sentiment score of 0.19 beat MaxCyte's score of 0.00 indicating that NIOX Group is being referred to more favorably in the media.
NIOX Group has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.
NIOX Group has higher earnings, but lower revenue than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.
Summary
NIOX Group beats MaxCyte on 10 of the 15 factors compared between the two stocks.
Get NIOX Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for NIOX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NIOX Group Competitors List
Related Companies and Tools
This page (LON:NIOX) was last updated on 1/21/2025 by MarketBeat.com Staff
Free NIOX Stock Alerts